MSCI World ETF's Record Run Faces a Fee War and Tariff Headwinds

The iShares MSCI World ETF reaches a new high but faces challenges from high fees, concentrated tech bets, and new US tariffs on pharmaceuticals.

The iShares MSCI World ETF (URTH) is trading at a 52-week high, with its net asset value reaching $193.15 in mid-April 2026. This rally, however, is built on a foundation of concentrated bets and is now confronting significant new pressures from competitive fees and looming policy changes.

A handful of US technology giants are steering the fund's performance. The tech sector accounts for 26.80% of the total portfolio weight. Nvidia is the top individual holding at 5.29%, followed by Apple at 4.55% and Microsoft at 3.17%. These three positions alone command 13.6% of the fund's assets. The ten largest holdings collectively represent over a quarter of the entire portfolio, underscoring a significant reliance on mega-cap performance.

Counterbalancing this tech dominance, the financial sector is delivering robust results. The first-quarter 2026 earnings season concluded with standout reports from major US banks. Morgan Stanley capped it off, seeing profit surge 29% to $5.57 billion on revenue of $20.58 billion, the first time the bank has crossed the $20 billion mark in a single quarter. Its equities trading revenue jumped 25% to a record $5.15 billion. JPMorgan Chase set the tone earlier, reporting record trading revenue of $11.6 billion for Q1, a 20% year-over-year increase. For the S&P 500 broadly, FactSet anticipates Q1 earnings growth of 12.5%, which would mark a sixth consecutive quarter of double-digit growth—the longest such streak in over a decade.

This performance has attracted substantial capital. The fund's assets under management swelled to approximately $7.82 billion in mid-April, supported by high daily trading activity exceeding one million shares. Institutional loyalty appears intact; the Royal Bank of Canada increased its position by 17.5% in Q4 2025 to about two million shares. Morningstar maintains a Bronze rating on the fund, which also holds a 5-star rating for long-term risk-adjusted returns.

Yet, the fund's 0.24% total expense ratio (TER) is coming under intense scrutiny. A fee war is heating up among competitors. Invesco cut the fee on its MSCI World ETF from 0.19% to 0.05% on April 1, following similar moves by UBS and BNP Paribas. This leaves URTH's fee 19 basis points above the cheapest rival. BlackRock defends its product by highlighting a tight tracking difference of just 0.02%, and Morningstar notes that while the fund is competitively positioned, it could be cheaper.

Looking ahead, two major challenges loom. First, new US tariffs on imported pharmaceutical products, announced in early April, could pressure the healthcare sector, which makes up 9.45% of the portfolio. The policy imposes a 100% tariff on companies without US pricing agreements, 15% on imports from the EU, Japan, South Korea, and Switzerland, and 10% on UK-made products, effective from the end of July 2026. Analysts project these measures could add roughly 0.5 percentage points to inflation and squeeze corporate margins.

Second, a significant index reshuffle is on the horizon. An MSCI review in May, implementing a new free-float classification system, is expected to trigger far larger portfolio adjustments than the moderate first-quarter review, which saw 18 additions and 27 deletions. The fund will also trade ex-dividend on June 15, 2026, following a year where dividend growth exceeded 20%.

Despite trading between a 52-week low of $143.98 and its recent peak, the ETF maintains broad exposure across 23 developed markets and multiple sectors. Financial services form the second-largest allocation at 16.17%, with industrials at 11.69%. This diversification provides a cushion, but the fund's path forward will be shaped by its ability to navigate concentrated bets, fee competition, and external policy shocks.